The role of CD133 in hepatocellular carcinoma.

Abstract

Cancer stem cells (CSCs) represent a small subpopulation of cells found within tumors that exhibit properties of self-renewal, like normal stem cells. CSCs have been defined as a crucial factor involved in driving cancer relapse, chemoresistance and metastasis. Prominin-1 (CD133) is one of the most well-characterized markers of CSCs in various tumor types, including hepatocellular carcinoma (HCC). CD133+ cells have been demonstrated to be involved in metastasis, tumorigenesis, tumor recurrence, and resistance to treatment in HCC. CD133-related clinical prognosis prediction, and targeted therapy have highlighted the clinical significance of CD133 in HCC. However, there remains controversy over the role of CD133 in experimental and clinical research involving HCC. In this article, we summarize the fundamental cell biology of CD133 in HCC cells and discuss the important characteristics of CD133+ in HCC cells. Furthermore, the prognostic value of CD133, and therapeutic strategies for its targeting in HCC, is also reviewed.

• Authors: Fengchao Liu, Yanzhi Qian
• Journal: Cancer biology & therapy (Cancer Biol Ther) Vol. 22 Issue 4 Pg. 291-300 (04 03 2021) ISSN: 1555-8576 [Electronic] United States
• PMID: 33899676 (Publication Type: Journal Article)

Chemical References

• AC133 Antigen
• PROM1 protein, human

Topics

• AC133 Antigen
• Carcinoma, Hepatocellular
• Cell Line, Tumor
• Humans
• Liver Neoplasms
• Neoplasm Recurrence, Local
• Neoplastic Stem Cells